Phase 1 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are older than 18 years of age.
- People who have given their documented, signed agreement to take part in the trial.
- People who have been diagnosed with non-small cell lung cancer (a type of lung cancer), confirmed by a tissue sample taken with a needle, and whose cancer has been classified as stage II or III (but not involving a specific lymph node classification called N2), and whose cancer is suitable for treatment with a combination of immunotherapy (nivolumab) and chemotherapy before surgery.
- People whose cancer cells test positive for a protein called PD-L1 at a level above 50%.
- People who have no history of immune system disorders, hepatitis B, hepatitis C, or HIV.
- Female participants who are not currently pregnant.
- Female participants who are capable of becoming pregnant and who agree to use a highly reliable form of contraception (with less than 1% chance of failure per year) or who consistently abstain from heterosexual intercourse as their usual lifestyle — both during the treatment period and for at least 180 days after the last dose — and who agree not to donate or store eggs for reproductive use during this time.
- Female participants who are capable of becoming pregnant and who have had a negative pregnancy test (urine or blood, depending on local requirements) within 24 hours (urine) or 72 hours (blood) before the first dose of treatment.
- People whose general physical condition and ability to carry out daily activities is rated at a level of 0 or 1 on a standard medical scale (meaning they are fully active or have only minor limitations).
- People whose blood, kidney, and liver function are considered healthy enough to receive the planned chemotherapy and immunotherapy combination, as assessed by the treating doctor.
- People who have signed the written consent form.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose lung cancer is located or classified in one of the following ways: in the upper groove of the chest area (superior sulcus), a type called large cell neuroendocrine cancer, or a type called sarcomatoid tumour.
- People who have a history of, or currently have, a lung inflammation condition (not caused by infection) called pneumonitis or interstitial lung disease that required steroid treatment.
- People who currently have an active infection that requires treatment with medication throughout the body (such as antibiotics or antivirals).
- People who have received a transplant of someone else's tissue or a solid organ.
- People who have any condition, past treatment, or abnormal test result that — in the treating doctor's opinion — could affect the trial results, prevent them from completing the full trial, or make participation not in their best interest.
- People who have known psychiatric conditions or substance use problems that would make it difficult to follow the requirements of the trial.
- People who have had another cancer that is still growing or required active treatment within the past 5 years. (Note: People who have had certain skin cancers, bladder cancer, or cancer confined to one area — such as cervical or breast carcinoma in situ — that were treated with the goal of cure are not excluded, confirm with trial site.)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Antoine Desilets, MD, MSc, Centre hospitalier de l'Université de Montréal (CHUM)
Phone: 514-890-8444
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety; Feasibility
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.